Antispasmodics Drugs Market Report 2026

The antispasmodics drugs market size has grown strongly in recent years. It will grow from $14.93 billion in 2025 to $16.34 billion in 2026 at a compound annual growth rate (CAGR) of 9.5%. The growth in the historic period can be attributed to rising incidence of ibs and stomach cramps, growing hospital pharmacy infrastructure, adoption of oral antispasmodic tablets, increasing awareness about gastrointestinal health, improvements in drug formulation technologies.

The antispasmodics drugs market size is expected to see strong growth in the next few years. It will grow to $23.47 billion in 2030 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to advancements in precision medicine, development of injectable and liquid antispasmodics, expansion of online pharmacy platforms, growing geriatric and pediatric patient population, integration of digital health monitoring systems. Major trends in the forecast period include personalized antispasmodic therapy, advanced drug delivery systems, increasing prevalence of gastrointestinal disorders, growing homecare medication adoption, rising focus on pediatric and geriatric patients.

The growing elderly population is expected to drive the growth of the antispasmodic drug market in the coming years. Individuals aged 65 years and older are considered elderly and are often associated with a range of physical and psychological health conditions. Antispasmodic drugs are beneficial for the elderly in managing symptoms related to various conditions that cause muscle spasms or cramping and may also be used for conditions such as irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), interstitial cystitis, and uterine cramping. For example, in July 2024, according to the UK Parliament’s House of Commons Library, a UK-based government administration, there were 12.7 million people aged 65 and above in the UK in 2022. This figure is projected to increase to 22.1 million by 2072, representing 27% of the total population. Therefore, the rising elderly population is contributing to the growth of the antispasmodic drug market.

The rising prevalence of irritable bowel syndrome (IBS) is expected to drive the growth of the antispasmodic drug market in the coming years. Irritable bowel syndrome is a common gastrointestinal disorder characterized by a collection of symptoms affecting the large intestine, leading to discomfort and disruption of normal digestive function. Antispasmodic drugs are widely used in the treatment of IBS to reduce muscle spasms and cramping in the gastrointestinal tract, thereby relieving abdominal pain and discomfort in patients. For example, in June 2024, according to the Centers for Disease Control and Prevention, a US-based federal agency, the estimated prevalence of inflammatory bowel disease (IBD) in the United States ranged from 2.4 to 3.1 million, with varying impacts across different population groups. Additionally, Oxford University Press, a UK-based publishing company, estimated that in 2023, approximately 322,600 Canadians were living with inflammatory bowel disease. Therefore, the increasing prevalence of irritable bowel syndrome is contributing to the growth of the antispasmodic drug market.

Major companies operating in the antispasmodics drug market are introducing new products to maintain their market position. For example, in January 2023, Lupin Limited, an India-based pharmaceutical company, launched Fesoterodine Fumarate after receiving approval from the Food and Drug Administration (FDA), a US-based federal government agency. Fesoterodine fumarate is a generic antispasmodic medication used to treat specific bladder conditions, including overactive bladder and neurogenic detrusor overactivity. It belongs to the antispasmodics drug class and functions by relaxing the bladder muscles. The medication is available in an extended-release tablet form.

Major companies operating in the antispasmodics drugs market are Daiichi Sankyo Company Limited, Fresenius Kabi AG, Hikma Pharmaceuticals plc, Johnson & Johnson Services Inc., Pfizer Inc., Shanghai Fosun Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Akorn Inc., Aurobindo Pharma Limited, Lannett Company Inc., Nexus Pharmaceuticals Inc., Actiza Pharmaceutical Private Limited, Blue Cross Laboratories Pvt. Ltd., Dr. Reddy's Laboratories Ltd., Lexicare Pharma Pvt. Ltd., Solitaire Pharmacia Private Limited, Strides Pharma Science Limited, Wellona Pharma Private Limited, SunGen Pharma LLC, GlaxoSmithKline plc, Novartis AG, Sanofi SA, AstraZeneca plc, Merck & Co. Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Endo Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Lupin Ltd.

North America was the largest region in the antispasmodics drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the antispasmodics drugs market report during the forecast period. The regions covered in the antispasmodics drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the antispasmodics drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the antispasmodics drugs market by increasing the cost of imported raw materials and active pharmaceutical ingredients, thereby affecting manufacturing and pricing strategies. Regions such as Asia-Pacific, where major production hubs are located, face higher cost pressures. Segments like injectable formulations and specialty drugs are most impacted due to complex supply chains. Some local manufacturers benefit by gaining competitive advantage in domestic markets, encouraging localized production and reducing dependency on imports. Overall, tariffs are reshaping sourcing strategies while prompting innovation in cost-effective drug delivery solutions.

The antispasmodics drugs market research report is one of a series of new reports that provides antispasmodics drugs market statistics, including antispasmodics drugs industry global market size, regional shares, competitors with a antispasmodics drugs market share, detailed antispasmodics drugs market segments, market trends and opportunities, and any further data you may need to thrive in the antispasmodics drugs industry. This antispasmodics drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Antispasmodic drugs are medications used to treat, prevent, or reduce the frequency of muscle spasms, particularly involving smooth muscles such as those found in the intestinal wall. These drugs act by slowing normal gut movements and relaxing the muscles of the stomach and intestines.

The primary drugs in the antispasmodics category include dicyclomine hydrochloride, loperamide hydrochloride, and others. Dicyclomine is an anticholinergic medication that helps reduce gastrointestinal muscle spasms by blocking the activity of a naturally occurring chemical in the body. The main indications include irritable bowel syndrome, stomach cramps, and other related conditions, and these drugs are administered through oral, parenteral, and other routes. Distribution channels include hospital pharmacies, online pharmacies, and retail pharmacies, with end-users such as hospitals, homecare settings, specialty clinics, and others.

The antispasmodics drugs market consists of sales of natural alkaloids such as atropine, belladonna, hyoscyamine, scopolamine, and related drugs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.